OKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trial

Chairman Gabriele Cerrone’s Increased Investment Demonstrates Confidence Ahead of Phase 3 Launch

Gabriele Cerrone’s recent share acquisition in OKYO Pharma underscores strong leadership confidence in the company’s strategic and clinical development trajectory. Through Panetta Partners Ltd, Cerrone acquired 25,000 ordinary shares at $1.40 each, committing $35,000 and increasing his substantial existing stake. This insider purchase precedes the company’s planned Phase 3 clinical trial, often interpreted by investors as a positive indicator ahead of key corporate milestones. Cerrone’s enhanced holding reflects belief in the growth potential arising from OKYO’s clinical pipeline and strategic direction, while providing transparency on his ongoing commitment.

The timing of this transaction is significant as it anticipates the initiation of a pivotal Phase 3 trial. Insider buying activity is frequently viewed favorably by the market, suggesting management’s confidence in upcoming clinical data and value creation. Cerrone’s decision to augment his stake signals optimism about OKYO’s prospects and aligns his financial interests with shareholder value enhancement.

OKYO Pharma’s Focus on Neuropathic Corneal Pain and Anterior Segment Eye Disease Therapeutics

As a clinical-stage biopharmaceutical company, OKYO Pharma concentrates on developing innovative therapies for neuropathic corneal pain (NCP) and diseases affecting the anterior segment of the eye. This targeted approach addresses significant unmet medical needs related to corneal nerve dysfunction and ocular surface disorders, which can severely impact patient quality of life. Neuropathic corneal pain involves nerve fiber abnormalities in the cornea, posing complex treatment challenges.

The anterior segment includes ocular structures such as the cornea, conjunctiva, iris, and lens, with diseases ranging from inflammatory to degenerative conditions. OKYO’s specialization in these areas differentiates it within the biopharmaceutical sector, enabling focused clinical development and regulatory strategies. The company’s clinical-stage status indicates ongoing trials without approved commercial products, emphasizing reliance on successful trial outcomes and regulatory approvals for growth.

Design and Enrollment Strategy for Urcosimod Phase 3 Single-Dose Trial

OKYO Pharma’s lead candidate, urcosimod, is set for a global Phase 3 pivotal clinical trial planned for the second half of 2026. The trial will evaluate a single-dose regimen, potentially offering simplified treatment and improved patient adherence if successful. Approximately 111 patients will be enrolled to assess urcosimod’s efficacy and safety in treating neuropathic corneal pain.

Phase 3 trials are critical milestones, serving as the foundation for regulatory submissions to agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). The global scope of the trial indicates a strategy to support regulatory approvals across multiple regions. The single-dose design may provide competitive advantages in clinical practice, enhancing patient and provider acceptance. Successful Phase 3 completion would significantly de-risk OKYO’s clinical program and facilitate potential regulatory approval and commercialization.

Chairman Cerrone’s Beneficial Ownership Surpasses 20% Threshold

Following the July 21, 2026 transaction, Gabriele Cerrone’s total ownership in OKYO Pharma reached 10,851,416 ordinary shares, representing 20.51% of issued share capital. This substantial stake positions him as a major shareholder with significant influence over corporate governance and strategic decisions. The disclosed ownership through Panetta Partners Ltd reflects a long-term investment perspective and alignment with shareholder interests.

Ownership exceeding 20% typically grants meaningful participation in shareholder voting and corporate matters. For investors, Cerrone’s sizeable stake signals insider confidence in OKYO’s clinical and strategic initiatives. Disclosure of this holding complies with securities regulations, ensuring transparency regarding related party interests and governance dynamics. Market participants should monitor any future changes in this stake as indicators of management sentiment.

Nasdaq Capital Market Listing and Public Shareholder Dynamics

OKYO Pharma’s ordinary shares trade on the Nasdaq Capital Market under the ticker symbol OKYO, providing liquidity and access for institutional and retail investors. The Nasdaq listing confers public company status, regulatory oversight, capital raising opportunities, and visibility within the investment community. This status supports transparent price discovery and efficient trading of shares.

The coexistence of significant insider holdings alongside public shareholders creates a balanced capital structure. Chairman Cerrone’s recent purchase at $1.40 per share offers a reference point for valuation, though immediate share price impact was not disclosed. Investors should consider insider transactions in the context of their own valuation and investment strategies. The public listing ensures ongoing disclosure and governance standards, facilitating informed market participation.

Development Timeline and Expectations for Phase 3 Trial Initiation

OKYO Pharma’s plan to initiate its Phase 3 clinical trial in the second half of 2026 sets a clear near-term milestone. Launching a global pivotal trial requires successful prior phase completions, regulatory approvals, and operational readiness for patient recruitment across multiple sites. The enrollment target of approximately 111 patients aligns with statistical requirements to support regulatory submissions.

Ophthalmology clinical trials can face challenges such as patient recruitment variability and geographic differences. While the announcement specifies trial start timing, it does not detail expected completion dates or regulatory review timelines. Investors will likely track updates on trial progress, enrollment, and any timeline adjustments through future company communications and financial reports.

Risk Profile of Clinical-Stage Biopharmaceutical Company

As a clinical-stage biopharmaceutical entity, OKYO Pharma’s operations and financial performance depend heavily on successful clinical development and regulatory approvals. Such companies face heightened risks including trial failures, regulatory setbacks, competitive pressures, and capital demands. The company did not disclose current funding or cash position in the announcement.

The upcoming Phase 3 trial of urcosimod represents a pivotal value inflection. Negative trial outcomes could materially affect valuation and regulatory prospects. Even with approval, market competition and adoption challenges remain. Investors should carefully assess clinical design, unmet medical needs, and competitive landscape when considering investment in OKYO Pharma, recognizing the distinct risk-reward dynamics compared to established pharmaceutical firms.

Corporate Governance, Leadership, and Investor Relations

OKYO Pharma operates under a structured governance framework led by Chairman Gabriele Cerrone. The company maintains offices in London and New York, reflecting its transatlantic focus and regulatory engagement in both European and North American markets. This dual presence facilitates coordination across corporate, regulatory, and commercial functions.

Investor relations and business development are managed by Paul Spencer, providing a dedicated contact for shareholder communications. The company offers contact details including a London telephone number and email for investor inquiries. Information dissemination is supported through Globe Newswire and the corporate website www.okyopharma.com, enhancing transparency and investor engagement.

Global Regulatory Strategy and International Trial Implications

The global design of OKYO Pharma’s Phase 3 trial reflects an intent to pursue regulatory approvals in multiple jurisdictions including the U.S. and Europe. International patient enrollment aims to build a comprehensive evidence base acceptable to diverse regulatory agencies. This approach broadens the potential market reach for urcosimod upon approval.

Regulatory requirements vary by region regarding trial design, endpoints, and safety assessments. Coordinating a global trial necessitates adherence to multiple regulatory guidelines to ensure data acceptance. While specific regulatory guidance and submission timelines were not disclosed, initial approval efforts are likely to focus on the U.S. market, supported by Nasdaq listing and North American infrastructure. The regulatory pathway is critical to OKYO Pharma’s commercial success and shareholder value over the multi-year development horizon.